Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive NSCLC Clinical Trial

Official title:
A Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04009317
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Li Zhang, Doctor
Phone	020-87343088
Email	zhangli@sysucc.org.cn
Status	Recruiting
Phase	Phase 3
Start date	August 13, 2019
Completion date	April 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05482087` - A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC	Phase 2
Active, not recruiting	`NCT02393625` - Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer	Phase 1
Recruiting	`NCT03804541` - The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human	Phase 1
Completed	`NCT04647110` - Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Recruiting	`NCT04056572` - Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib	Phase 2